ASRS 2023: Long-term outcomes of IOP-lowering medication in the PALADIN trial

Veena Raiji, MD, MPH, spoke with our team about long-term outcomes of eyes requiring IOP-lowering medication in the PALADIN trial at the 2023 ASRS annual meeting.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Veena Raiji, MD, MPH:

Hi, my name is Veena Raji. I'm am a retina uveitis specialist at Illinois Retina Associates in Chicago, Illinois. Today I'd like to share with you the long term outcomes of eyes requiring IOP-lowering medication in the PALADIN trial which, was a 36 month trial looking at eyes that had received fluocinolone acetonide 0.19(-mg) therapy for the treatment of diabetic macular edema. In total, 202 eyes were studied out to about 36 months. Roughly 11% of eyes had an IOP elevation greater than 30 millimeters of mercury, [with] at least 1 study visit. The vast majority of eyes that had an IOP elevation were managed with just 1 IOP drop. The conclusion of this study was that 70% of patients had no IOP related events and patients that did have IOP related events still had excellent outcomes with regards to visual acuity, anatomic outcomes, and reduction in need for treatment for diabetic macular edema. Thank you.